Befotertinib in Patients With EGFR T790M–Mutated NSCLC Who Progressed After Prior EGFR TKI Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
J Thorac Oncol 2022 Jun 18;[EPub Ahead of Print], S Lu, Y Zhang, G Zhang, J Zhou, S Cang, Y Cheng, G Wu, P Cao, D Lv, H Jian, C Chen, X Jin, P Tian, K Wang, G Jiang, G Chen, Q Chen, H Zhao, C Ding, R Guo, G Sun, B Wang, L Jiang, Z Liu, J Fang, J Yang, W Zhuang, Y Liu, J Zhang, Y Pan, J Chen, Q Yu, M Zhao, J Cui, D Li, T Yi, Z Yu, Y Yang, Y Zhang, X Zhi, Y Huang, R Wu, L Chen, A Zang, L Cao, Q Li, X Li, Y Song, D Wang, S Zhang, L Ding, L Zhang, X Yuan, L Yao, Z ShenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.